30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Portfolio Pulse from Lara Goldstein
The psychedelics industry is experiencing rapid growth, with the global market projected to reach $7.1 billion by 2032. The article highlights 30 influential figures in the field, including executives, scientists, and advocates, who are driving innovation and acceptance of psychedelic medicines. Among the notable individuals are Janet Qi of PurMinds Neuropharma, Dr. Anna Yusim, Kristina Spionjak of HLTH Communications, Marik Hazan of Tabula Rasa Ventures, Shayla Love, Doug Drysdale of Cybin Inc. (NYSE:CYBN), Dr. Beatriz Caiuby Labate of MAPS, Dr. David Meiri, Nataliya Vorobyeva of Hive Bio, Dr. Joseph Tucker of Enveric Biosciences (NASDAQ:ENVB), Amanda Siebert, Mattha Busby, Dennis Walker of Mycopreneur, Graham Pechenik, Rick Doblin of MAPS PBC, Jules Evans, Prof. David Nutt, Dr. Peter Grinspoon, Dr. Nolan Williams, Genevieve and Steve Jurvetson (Steve is an early VC investor in Tesla (NASDAQ:TSLA)), Reilly Capps, Payton Nyquvest of Numinus Wellness (OTC:NUMIF), Andrew Huberman, Dr. Max Wolff, Amanda Feilding, Dr. Rachel Yehuda, Dr. Mason Marks, David B. Yaden, and Dr. Robin Carhart-Harris. The article emphasizes the diverse backgrounds and contributions of these individuals to the advancement of psychedelic therapy for mental health.
January 11, 2024 | 12:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Steve Jurvetson, an early VC investor in Tesla, is also a major supporter of psychedelic-assisted therapy research. While not directly related to Tesla's core business, this could reflect positively on the company's innovative culture.
Although Steve Jurvetson's support for psychedelic research is not directly related to Tesla's operations, his association with both Tesla and innovative sectors like psychedelics could have a neutral to slightly positive impact on Tesla's image as an innovative company. However, this is unlikely to have a significant short-term impact on the stock price.
CONFIDENCE 60
IMPORTANCE 20
RELEVANCE 30
POSITIVE IMPACT
Doug Drysdale, CEO of Cybin Inc., has led the company to a significant increase in value and capital raising. His leadership and the company's progress in the psychedelics space could positively influence investor sentiment.
The article highlights Doug Drysdale's successful efforts in increasing Cybin Inc.'s value and raising substantial capital. As the psychedelics industry grows, Cybin's advancements could lead to increased investor interest and a potential positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Dr. Joseph Tucker, CEO of Enveric Biosciences, has a track record of building successful biotech companies. His current role at ENVB and his experience could be a positive signal for investors.
The article mentions Dr. Joseph Tucker's role as CEO of Enveric Biosciences and his previous successes in the biotech industry. This could be perceived positively by investors, potentially leading to a short-term positive impact on ENVB's stock price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Payton Nyquvest, founder and CEO of Numinus Wellness, is working on advancing psychedelic-assisted therapies. The company's involvement in clinical trials and mental health services could attract investor interest.
The article discusses Payton Nyquvest's role in Numinus Wellness and its focus on psychedelic-assisted therapies. As the industry grows, Numinus's active involvement in research and mental health services could have a positive short-term impact on its stock price.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 65